IP Library Granted Patent US 9,974,811
Granted Patent B2
US 9,974,811 · App. 12/416,700 · Granted May 22, 2018

Multipotent adult stem cells and methods for isolation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,974,811
App. No.
12/416,700
Granted
May 22, 2018
Kind
B2
Abstract

The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.

Claims (13)

1. A cell culture comprising isolated expanded human non-embryonic, non-germ cells that are obtained by culture of non-embryonic, non-germ tissue, the cells having undergone 40 cell doublings in culture, wherein the cells have a normal karyotype.

2. The cell culture of claim 1 wherein the non-embryonic, non-germ cells express one or more of oct4, telomerase, rex-1, rox-1, or sox-2.

3. The cell culture of claim 1 wherein the non-embryonic, non-germ cells can differentiate into at least one cell type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.

4. The cell culture of claim 3 wherein the non-embryonic, non-germ cells express one or more of oct4, telomerase, rex-1, rox-1, or sox-2.

5. The cell culture of claim 3 wherein the non-embryonic, non-germ cells can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.

6. The cell culture of claim 5 wherein the non-embryonic, non-germ cells express one or more of oct4, telomerase, rex-1, rox-1, or sox-2.

7. A pharmaceutical composition comprising the isolated expanded non-embryonic, non-germ cells of claim 1 in a pharmaceutically acceptable carrier.

8. A method for making the pharmaceutical composition of claim 7 comprising admixing the isolated expanded non-embryonic, non-germ cells with a pharmaceutically acceptable carrier.

9. A method for making a cell culture composition, said method comprising introducing the isolated expanded human non-embryonic, non-germ cells of claim 1 into cell culture medium.

10. The cell culture of any of claim 1 - 6 wherein the isolated expanded human non-embryonic, non-germ cells are derived from bone marrow.

11. The pharmaceutical composition of claim 7 wherein the isolated expanded human non-embryonic, non-germ cells are derived from bone marrow.

12. The method of claim 8 wherein the isolated expanded human non-embryonic, non-germ cells are derived from bone marrow.

13. The method of claim 9 wherein the isolated expanded human non-embryonic, non-germ cells are derived from bone marrow.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 067606/0139 →
RELEASE OF SECURITY INTEREST Recorded May 29, 2024
From: HEALIOS K.K.
To: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
Reel/Frame 067566/0638 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 1, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 066435/0775 →